The London Life Sciences team advised Jeito Capital on leading an oversubscribed $92 million Series C financing round in Pulmocide.
Jeito is an independent private equity firm dedicated to biotech and biopharma with a patient benefit driven approach that focuses both on financing ground-breaking medical innovation and promoting positive societal impact.
Pulmocide is a late-stage biopharmaceutical company developing novel therapies for patients suffering from serious acute and chronic respiratory diseases.
Proceeds from the financing will be primarily used to advance Pulmocide’s lead asset PC945 for the treatment of Invasive Pulmonary Aspergillosis, through a Phase III registration program in patients who have failed prior therapy. The financing will also help fund the planning and development of the Company’s commercial operations for PC945 starting with the US and Europe, and begin exploring the use of the compound in other clinical, chronic indications.
The Goodwin team was led by Sophie McGrath and included Kenny Walker-Durrant and Matthew Shelley.
For more details, read the press release.